Assetmark Inc. Has $118,000 Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Assetmark Inc. reduced its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 15.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,412 shares of the company’s stock after selling 800 shares during the quarter. Assetmark Inc.’s holdings in Castle Biosciences were worth $118,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Castle Biosciences by 147.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,458 shares of the company’s stock worth $4,719,000 after purchasing an additional 98,571 shares in the last quarter. Barclays PLC increased its holdings in Castle Biosciences by 310.7% in the third quarter. Barclays PLC now owns 52,301 shares of the company’s stock worth $1,491,000 after purchasing an additional 39,567 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Castle Biosciences by 165.2% in the third quarter. JPMorgan Chase & Co. now owns 69,409 shares of the company’s stock worth $1,980,000 after purchasing an additional 43,241 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Castle Biosciences by 16.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 274,761 shares of the company’s stock worth $7,836,000 after purchasing an additional 39,417 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Castle Biosciences by 1.1% in the third quarter. Geode Capital Management LLC now owns 624,683 shares of the company’s stock worth $17,820,000 after purchasing an additional 7,004 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Stephens restated an “overweight” rating and set a $41.00 price objective on shares of Castle Biosciences in a report on Thursday, January 2nd. Robert W. Baird upped their price target on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Castle Biosciences presently has a consensus rating of “Buy” and an average target price of $40.00.

Insider Activity

In other news, insider Derek J. Maetzold sold 2,715 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $29.62, for a total value of $80,418.30. Following the completion of the transaction, the insider now owns 82,047 shares in the company, valued at $2,430,232.14. This trade represents a 3.20 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Daniel Bradbury sold 7,867 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total value of $221,613.39. The disclosure for this sale can be found here. Insiders sold a total of 53,568 shares of company stock worth $1,321,364 in the last quarter. 7.20% of the stock is owned by company insiders.

Castle Biosciences Trading Up 2.8 %

CSTL opened at $19.29 on Friday. The stock has a market cap of $540.26 million, a PE ratio of 96.45 and a beta of 0.98. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. The business has a 50 day moving average of $25.80 and a 200-day moving average of $28.63. Castle Biosciences, Inc. has a 52 week low of $16.97 and a 52 week high of $35.84.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.